BridgeBio reports early Attruby demand: 430 scripts from 248 physicians; three Phase 3 trials fully enrolled

BridgeBio Pharma, Inc.

Attruby (acoramidis) approved Nov 22, 2024; 430 prescriptions by 248 unique HCPs since launch.
Three Phase 3 trials fully enrolled: FORTIFY (LGMD2I/R9, n=112), CALIBRATE (ADH1, n=70), PROPEL 3 (achondroplasia, n=114).
Cash $406M last quarter; received $500M upon acoramidis FDA approval from royalty facility; expects $105M milestones in 1H 2025.
Milestones: EU/Japan acoramidis approvals in 1H 2025; topline readouts FORTIFY & CALIBRATE in 2H 2025; PROPEL 3 LPLV in 2H 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.